Compare NSSC & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSSC | GLPG |
|---|---|---|
| Founded | 1969 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | 452 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 1994 | N/A |
| Metric | NSSC | GLPG |
|---|---|---|
| Price | $36.36 | $27.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $48.17 | $36.50 |
| AVG Volume (30 Days) | ★ 376.0K | 159.1K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $181,621,000.00 | N/A |
| Revenue This Year | $13.63 | N/A |
| Revenue Next Year | $10.05 | N/A |
| P/E Ratio | $52.99 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.44 | $26.62 |
| 52 Week High | $47.61 | $37.78 |
| Indicator | NSSC | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 33.99 | 36.53 |
| Support Level | $35.89 | N/A |
| Resistance Level | $44.43 | $34.04 |
| Average True Range (ATR) | 1.33 | 0.56 |
| MACD | -0.20 | 0.08 |
| Stochastic Oscillator | 15.15 | 25.33 |
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.